

Jocelyn Dupuis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3924525/publications.pdf>

Version: 2024-02-01

144
papers

9,137
citations

87723

38
h-index

40881

93
g-index

159
all docs

159
docs citations

159
times ranked

8825
citing authors

#	ARTICLE	IF	CITATIONS
1	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. <i>New England Journal of Medicine</i> , 2003, 349, 1893-1906.	13.9	2,240
2	Cellular and Molecular Basis of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S20-S31.	1.2	714
3	Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. <i>Circulation</i> , 1999, 99, 3227-3233.	1.6	497
4	Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1. <i>Circulation</i> , 1996, 94, 1578-1584.	1.6	258
5	Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ET _B receptors. <i>Journal of Applied Physiology</i> , 1996, 81, 1510-1515.	1.2	254
6	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	5.2	218
7	Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. <i>Journal of the American College of Cardiology</i> , 1990, 16, 923-931.	1.2	200
8	Endothelin receptor antagonists in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2008, 31, 407-415.	3.1	185
9	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	0.8	181
10	Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2046.	3.8	146
11	Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 642-649.	0.4	111
12	A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors. <i>American Journal of Pathology</i> , 2018, 188, 1132-1148.	1.9	102
13	Effectiveness of a Nonselective ETA/B and a Selective ETA Antagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension. <i>Circulation</i> , 2001, 103, 314-318.	1.6	100
14	Short-Term Administration of a Cell-Permeable Caveolin-1 Peptide Prevents the Development of Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy. <i>Circulation</i> , 2006, 114, 912-920.	1.6	96
15	Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. <i>American Heart Journal</i> , 1998, 135, 614-620.	1.2	91
16	Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. <i>Cardiovascular Research</i> , 2004, 63, 747-755.	1.8	79
17	Endothelin A Receptor Blockade Improves Nitric Oxide-Mediated Vasodilation in Monocrotaline-Induced Pulmonary Hypertension. <i>Circulation</i> , 1998, 97, 2169-2174.	1.6	73
18	Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. <i>Circulation Research</i> , 2019, 125, 449-466.	2.0	73

#	ARTICLE	IF	CITATIONS
19	A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study). <i>American Heart Journal</i> , 2005, 150, 933.e9-933.e13.	1.2	71
20	Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. <i>Cardiovascular Research</i> , 2003, 58, 621-631.	1.8	68
21	Association Between Clinical Depression and Endothelial Function Measured by Forearm Hyperemic Reactivity. <i>Psychosomatic Medicine</i> , 2010, 72, 20-26.	1.3	63
22	Paradoxical decrease in circulating neuropeptide Y-like immunoreactivity during mild orthostatic stress in subjects with and without congestive heart failure. <i>European Heart Journal</i> , 1993, 14, 34-39.	1.0	62
23	Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. <i>American Journal of Cardiology</i> , 1999, 84, 952-954.	0.7	60
24	Reduced Pulmonary Clearance of Endothelin-1 Contributes to the Increase of Circulating Levels in Heart Failure Secondary to Myocardial Infarction. <i>Circulation</i> , 1998, 98, 1684-1687.	1.6	59
25	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI's Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1661-1670.	2.5	59
26	Endothelin-1-Induced Pulmonary Vasoreactivity Is Regulated by ET _A and ET _B Receptor Interactions. <i>Journal of Vascular Research</i> , 2007, 44, 375-381.	0.6	57
27	Absence of Association Between Infectious Agents and Endothelial Function in Healthy Young Men. <i>Circulation</i> , 2003, 107, 1966-1971.	1.6	56
28	Etiology-Specific Endothelin-1 Clearance in Human Precapillary Pulmonary Hypertension. <i>Chest</i> , 2006, 129, 689-695.	0.4	55
29	Importance of Local Production of Endothelin-1 and of the ETB Receptor in the Regulation of Pulmonary Vascular Tone. <i>Pulmonary Pharmacology and Therapeutics</i> , 2000, 13, 135-140.	1.1	54
30	Resident Nestin + Neural-Like Cells and Fibers Are Detected in Normal and Damaged Rat Myocardium. <i>Hypertension</i> , 2005, 46, 1219-1225.	1.3	54
31	The endothelin system in pulmonary hypertension. <i>Canadian Journal of Physiology and Pharmacology</i> , 2003, 81, 542-554.	0.7	51
32	Endothelin-receptor antagonists in pulmonary hypertension. <i>Lancet</i> , The, 2001, 358, 1113-1114.	6.3	50
33	Near-Infrared Spectroscopy to Monitor Peripheral Blood Flow Perfusion. <i>Journal of Clinical Monitoring and Computing</i> , 2008, 22, 37-43.	0.7	48
34	Randomized Controlled Trial of Tailored Nursing Interventions to Improve Cardiac Rehabilitation Enrollment. <i>Nursing Research</i> , 2012, 61, 111-120.	0.8	45
35	Intravascular Ultrasound Assessment of Pulmonary Vascular Disease in Patients With Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 809-815.	0.4	43
36	Pulmonary removal and production of endothelin in the anesthetized dog. <i>Journal of Applied Physiology</i> , 1994, 76, 694-700.	1.2	40

#	ARTICLE	IF	CITATIONS
37	Intensity of Lipid Lowering With Statins and Brachial Artery Vascular Endothelium Reactivity After Acute Coronary Syndromes (from the BRAVER Trial). <i>American Journal of Cardiology</i> , 2005, 96, 1207-1213.	0.7	39
38	Sustained beneficial effect of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure. <i>American Heart Journal</i> , 1990, 120, 625-637.	1.2	38
39	Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. <i>Clinical Science</i> , 2005, 109, 97-102.	1.8	37
40	Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: Role of ETB-receptor expression levels. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 311-317.	1.1	34
41	Reduced pulmonary clearance of endothelin in congestive heart failure: a marker of secondary pulmonary hypertension. <i>Journal of Cardiac Failure</i> , 2004, 10, 427-432.	0.7	33
42	Pathophysiology and Clinical Relevance of Pulmonary Remodelling in Pulmonary Hypertension due to Left Heart Diseases. <i>Canadian Journal of Cardiology</i> , 2015, 31, 416-429.	0.8	33
43	Chronically Elevated Endothelin Levels Reduce Pulmonary Vascular Reactivity to Nitric Oxide. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 506-513.	2.5	31
44	Discovery of new antagonists aimed at discriminating ET_A and ET_B -mediated biological activities: insight into ET_A and ET_B receptor activation. <i>British Journal of Pharmacology</i> , 2013, 168, 807-821.	2.7	31
45	Lung Capillary Stress Failure and Arteriolar Remodelling in Pulmonary Hypertension Associated with Left Heart Disease (Group 2 PH). <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 11-21.	1.6	30
46	LU135252, an endothelinA receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. <i>British Journal of Pharmacology</i> , 2000, 130, 1525-1530.	2.7	29
47	Spermine on Endothelial Extracellular Vesicles Mediates Smoking-Induced Pulmonary Hypertension Partially Through Calcium-Sensing Receptor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 482-495.	1.1	29
48	Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. <i>Clinical Science</i> , 2003, 105, 647-653.	1.8	28
49	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. <i>PLoS ONE</i> , 2020, 15, e0242318.	1.1	28
50	Pulmonary angiotensin-converting enzyme substrate hydrolysis during exercise. <i>Journal of Applied Physiology</i> , 1992, 72, 1868-1886.	1.2	27
51	Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. <i>Biochemical Pharmacology</i> , 2012, 83, 608-615.	2.0	25
52	Impact of Pituitary-Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men. <i>Hypertension</i> , 2018, 72, 151-158.	1.3	25
53	Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. <i>Experimental Biology and Medicine</i> , 2006, 231, 840-6.	1.1	24
54	Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. <i>American Journal of Cardiology</i> , 2001, 87, 375-380.	0.7	23

#	ARTICLE	IF	CITATIONS
55	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.4	23
56	Lung capillary injury and repair in left heart disease: a new target for therapy?. Clinical Science, 2014, 127, 65-76.	1.8	23
57	Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clinical Science, 2006, 111, 217-224.	1.8	22
58	Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. European Respiratory Journal, 2011, 37, 578-586.	3.1	22
59	Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovascular Research, 1998, 39, 609-616.	1.8	21
60	Mechanisms of acute coronary syndromes and the potential role of statins. Atherosclerosis Supplements, 2001, 2, 9-14.	1.2	21
61	Relative associations between depression and anxiety on adverse cardiovascular events: does a history of coronary artery disease matter? A prospective observational study. BMJ Open, 2015, 5, e006582.	0.8	21
62	Use of norepinephrine uptake to measure lung capillary recruitment with exercise. Journal of Applied Physiology, 1990, 68, 700-713.	1.2	20
63	Beneficial Effects of Atorvastatin on Lung Structural Remodeling and Function in Ischemic Heart Failure. Journal of Cardiac Failure, 2010, 16, 679-688.	0.7	20
64	The research on endothelial function in women and men at risk for cardiovascular disease (REWARD) study: methodology. BMC Cardiovascular Disorders, 2011, 11, 50.	0.7	20
65	Endothelin-1 Regulates Tone of Isolated Small Arteries in the Rat. Hypertension, 1998, 31, 1035-1041.	1.3	19
66	Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging: A new marker of coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1473-1477.	1.2	19
67	Nestin is a Marker of Lung Remodeling Secondary to Myocardial Infarction and Type I Diabetes in the Rat. Journal of Cellular Physiology, 2015, 230, 170-179.	2.0	19
68	Randomized Trial Comparing Intravenous Nitroglycerin and Heparin for Treatment of Unstable Angina Secondary to Restenosis After Coronary Artery Angioplasty. Circulation, 2000, 101, 955-961.	1.6	18
69	Endothelin: setting the scene in PAH. European Respiratory Review, 2007, 16, 3-7.	3.0	18
70	Phenylalanine induces pulmonary hypertension through calcium-sensing receptor activation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L1010-L1020.	1.3	18
71	The ETA-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 33-39.	1.0	17
72	Reduction in hepatic endothelin-1 clearance in cirrhosis. Clinical Science, 2003, 105, 227-234.	1.8	17

#	ARTICLE	IF	CITATIONS
73	Radionuclide plethysmography for noninvasive evaluation of peripheral arterial blood flow. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 289, H258-H262.	1.5	16
74	Expression of Phosphoinositide-Specific Phospholipase C Isoforms in Native Endothelial Cells. <i>PLoS ONE</i> , 2015, 10, e0123769.	1.1	16
75	Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 450-464.	1.4	16
76	Sex- and Gender-Related Factors Associated With Cardiac Rehabilitation Enrollment. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2019, 39, 259-265.	1.2	15
77	Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension. <i>Circulation</i> , 2021, 143, 1775-1792.	1.6	15
78	Bone marrow-derived progenitor cells contribute to lung remodelling after myocardial infarction. <i>Cardiovascular Pathology</i> , 2007, 16, 321-328.	0.7	14
79	Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice. <i>Scientific Reports</i> , 2018, 8, 1363.	1.6	14
80	PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure. <i>Cardiovascular Research</i> , 2020, 116, 171-182.	1.8	14
81	Nitrates in congestive heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 501-507.	1.3	13
82	Kinetics of pulmonary uptake of serotonin during exercise in dogs. <i>Journal of Applied Physiology</i> , 1996, 80, 30-46.	1.2	13
83	L-arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. <i>Annals of Thoracic Surgery</i> , 1997, 64, 414-420.	0.7	13
84	Role of ET _A receptors in the regulation of vascular reactivity in rats with congestive heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H844-H851.	1.5	13
85	Pulmonary metabolism of endothelin 1 during on-pump and beating heart coronary artery bypass operations. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 121, 1137-1142.	0.4	13
86	Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1473-1477.	1.2	13
87	Use of Adrenomedullin Derivatives for Molecular Imaging of Pulmonary Circulation. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1869-1874.	2.8	13
88	Arterial flow measurements during reactive hyperemia using NIRS. <i>Physiological Measurement</i> , 2008, 29, 1033-1040.	1.2	13
89	Demographics, treatment and outcome of acute coronary syndromes: 17 years of experience in a specialized cardiac centre. <i>Canadian Journal of Cardiology</i> , 2006, 22, 121-124.	0.8	12
90	Kinetic analysis of pulmonary neutrophil retention in vivo using the multiple-indicator-dilution technique. <i>Journal of Applied Physiology</i> , 2003, 95, 279-291.	1.2	11

#	ARTICLE	IF	CITATIONS
91	Molecular Imaging of Monocrotaline-Induced Pulmonary Vascular Disease with Radiolabeled Linear Adrenomedullin. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1110-1115.	2.8	11
92	PulmoBind, an Adrenomedullin-Based Molecular Lung Imaging Tool. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1789-1796.	2.8	11
93	Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1136-1144.	3.3	11
94	Al[18F]F-complexation of DFH17, a NOTA-conjugated adrenomedullin analog, for PET imaging of pulmonary circulation. <i>Nuclear Medicine and Biology</i> , 2018, 67, 36-42.	0.3	11
95	PulmoBind Imaging Measures Reduction of Vascular Adrenomedullin Receptor Activity with Lack of effect of Sildenafil in Pulmonary Hypertension. <i>Scientific Reports</i> , 2019, 9, 6609.	1.6	11
96	Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G905-G914.	1.6	9
97	Role of endothelin receptors on basal and endothelin-1-stimulated lung myofibroblast proliferation. This article is one of a selection of papers published in the special issue (part 1 of 2) on <i>Frontiers in Endothelin</i> . <i>Canadian Journal of Physiology and Pharmacology</i> , 2008, 86, 337-342.	0.7	9
98	Single measurement of troponin T for early prediction of infarct size, congestive heart failure, and pulmonary hypertension in an animal model of myocardial infarction. <i>Cardiovascular Pathology</i> , 2011, 20, e85-e89.	0.7	9
99	Molecular Imaging of the Human Pulmonary Vascular Endothelium Using an Adrenomedullin Receptor Ligand. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00003.	0.7	9
100	Endothelial and Epithelial Cell Transition to a Mesenchymal Phenotype Was Delineated by Nestin Expression. <i>Journal of Cellular Physiology</i> , 2016, 231, 1601-1610.	2.0	9
101	Effect of ETAR Receptor Antagonist on Pulmonary Hypertension and Vascular Reactivity in Rats With Congestive Heart Failure. <i>Pulmonary Pharmacology and Therapeutics</i> , 2001, 14, 307-314.	1.1	8
102	Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging. <i>European Journal of Pharmacology</i> , 2009, 617, 118-123.	1.7	8
103	Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 72.	0.7	8
104	Molecular imaging of the pulmonary circulation in health and disease. <i>Clinical and Translational Imaging</i> , 2014, 2, 415-426.	1.1	8
105	Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L798-L809.	1.3	8
106	Endothelin-3-dependent pulmonary vasoconstriction in monocrotaline-induced pulmonary arterial hypertension. <i>Peptides</i> , 2008, 29, 2039-2045.	1.2	7
107	Characterization and reproducibility of forearm arterial flow during reactive hyperemia. <i>Physiological Measurement</i> , 2010, 31, 763-773.	1.2	6
108	Cardiopulmonary Bypass Is Associated With Altered Vascular Reactivity of Isolated Pulmonary Artery in a Porcine Model: Therapeutic Potential of Inhaled Tezosentan. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 698-708.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Endothelin-1 myocardial clearance, production, and effect on capillary permeability in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1239-H1245.	1.5	5
110	In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H17-H22.	1.5	5
111	Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine. Nuclear Medicine and Biology, 2011, 38, 867-874.	0.3	5
112	Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status. Metabolites, 2021, 11, 196.	1.3	5
113	Peptide Blocking Self-Polymerization of Extracellular Calcium-Sensing Receptor Attenuates Hypoxia-Induced Pulmonary Hypertension. Hypertension, 2021, 78, 1605-1616.	1.3	5
114	Evaluation of Luminal Endothelin-Converting Enzyme Activity in the Pulmonary and Coronary Circulations. Journal of Cardiovascular Pharmacology, 2004, 43, 21-25.	0.8	4
115	Evaluation of pulmonary perfusion by SPECT imaging using an endothelial cell tracer in supine humans and dogs. EJNMMI Research, 2016, 6, 43.	1.1	4
116	Positive and Negative Affect Is Related to Experiencing Chest Pain During Exercise-Induced Myocardial Ischemia. Psychosomatic Medicine, 2017, 79, 395-403.	1.3	4
117	A web-based tailored nursing intervention (TAVIE en m@rche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial. Journal of Advanced Nursing, 2019, 75, 2727-2741.	1.5	4
118	Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility. Hypertension, 2022, 79, 1348-1360.	1.3	4
119	Increased endothelin levels in congestive heart failure: does it come from the lungs? Does it matter?. Cardiovascular Research, 2004, 63, 5-7.	1.8	3
120	Evaluation of a Web-Based Tailored Nursing Intervention (TAVIE en m@rche) Aimed at Increasing Walking After an Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial Protocol. JMIR Research Protocols, 2017, 6, e64.	0.5	3
121	Mobile detection system to evaluate reactive hyperemia using radionuclide plethysmography. Physiological Measurement, 2007, 28, 953-962.	1.2	2
122	SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 203-215.	1.0	2
123	Noninvasive evaluation of endothelial vascular reactivity: should the quest continue?. Canadian Journal of Cardiology, 2005, 21, 1047-51.	0.8	2
124	Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors. Journal of the American College of Cardiology, 1996, 27, 104.	1.2	1
125	Effect of sternotomy and extracorporeal circulation on pulmonary neutrophil kinetics in pigs. Basic Research in Cardiology, 2006, 101, 133-139.	2.5	1
126	Downregulation of the Endothelin System of Lung Myofibroblasts in Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 2009, 54, 147-153.	0.8	1

#	ARTICLE	IF	CITATIONS
127	513 Elevated Osteopontin Levels in Patients With Chronic Heart Failure: Describing a Specific Physiopathological Process. Canadian Journal of Cardiology, 2012, 28, S289.	0.8	1
128	Pulmonary Production of Osteopontin in Humans: Effects of Left Ventricular Systolic Dysfunction and Cardiopulmonary Bypass. Journal of Cardiac Failure, 2013, 19, 816-820.	0.7	1
129	A Novel Molecular Pathway of Plaque Vulnerability Reveals a Cholesterol-Independent Effect of Statins and Supports Inflammation as a Therapeutic Target. Canadian Journal of Cardiology, 2020, 36, 1710-1713.	0.8	1
130	Animal Models of Pulmonary Hypertension. , 2011, , 453-458.		1
131	Nitrates in Congestive Heart Failure. , 1997, , 191-203.		1
132	A Web-Based Tailored Intervention to Support Illness Management in Patients With an Acute Coronary Syndrome: Pilot Study. JMIR Cardio, 2017, 1, e4.	0.7	1
133	The pulmonary circulation is an important site for both clearance and production of endothelin-1 in humans. Journal of the American College of Cardiology, 1996, 27, 218.	1.2	0
134	Role Of Bosentan On Lung Structural Remodeling And Pulmonary Function In Ischemic Heart Failure. , 2010, , .		0
135	Cardiopulmonary Bypass Is Associated with Pulmonary Artery Endothelial Dysfunction: Therapeutic Potential of Tezosentan. Journal of Heart and Lung Transplantation, 2013, 32, S205.	0.3	0
136	Secular Trends and Outcome of Isolated versus Combined Type 2 Pulmonary Hypertension in Patients with End-Stage Heart Failure. Journal of Heart and Lung Transplantation, 2019, 38, S486-S487.	0.3	0
137	SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer. Respiratory Research, 2021, 22, 240.	1.4	0
138	Effect of sternotomy and extracorporeal circulation on pulmonary neutrophil kinetics in pigs. FASEB Journal, 2006, 20, A282.	0.2	0
139	Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. Journal of the American College of Cardiology, 1998, 31, 380A.	1.2	0
140	Late Breaking Abstract - Inflammation and metabolic syndrome exacerbate pulmonary hypertension associated with left heart disease. , 2019, , .		0
141	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
142	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
143	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
144	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0